| Research backgroundMalignant bone tumor belongs to a rare group of heterogeneous tumors, which represents less than 1% of all adult and 15% of pediatric malignancies. The incidence of bone sarcoma is approximately 1.060 to 1.112 per 100 thousand. The mortality of bone and joint sarcoma comprises 1.6% of all cancer. Due to the huge population of our country, the number of annually new cases is definitely considerable. Currently, the therapy for bone sarcoma is mainly removing the local lesion through surgery, cooperated with auxiliary treatments of system chemicals, local radiation or bio-therapy.Post-surgery local bone defects may result in a series of problems, such as destruction of supporting structure, deprivation of motor functions, deformation of body or infective diseases. Because most chemicals have non-selective (or low-selective) lethal effect, traditional chemo-project could lead to lesion of other important organs like liver, kidney and marrow. Also, it is difficult to reach an effective concentration among post-operation local bone tissue, and the adverse reaction may be increased on a raising dosage.Calcium phosphate cement (CPC), a new type of non-ceramic, bioactive hydroxyapatite, has been developed and used as bone graft substitute in recent years. It could be implanted into body as a carrier of drug delivery system and serve the multifunction of repairing bone defect and decreasing the adverse reactions of some chemicals. The biologic characteristics of CPC are as... |
PDF Full Text Request